Targeting intratumoral heterogeneity in TNBC with novel combinations of FDA-approved drugs

被引：0
|
作者：
Truchan, Nathan A. [1 ]
Burnett, Joseph P. [1 ]
Sun, Duxin [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-968
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
968
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Peters, Eric J.
    Motsinger-Reif, Alison
    Havener, Tammy M.
    Everitt, Lorraine
    Hardison, Nicholas E.
    Watson, Venita G.
    Wagner, Michael
    Richards, Kristy L.
    Province, Mike A.
    McLeod, Howard L.
    PHARMACOGENOMICS, 2011, 12 (10) : 1407 - 1415
  • [32] Repurposing FDA-approved drugs as potential PARP inhibitors
    Eznarriaga, Maria
    Rahman, Taufiq
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2516 - 2516
  • [33] RNA as an off-target for FDA-approved drugs
    Fullenkamp, Christopher R.
    Schneekloth, John S.
    NATURE CHEMISTRY, 2023, 15 (10) : 1329 - 1331
  • [34] Pharmacogenetic Labeling of FDA-Approved Drugs A Regulatory Retrospective
    Drozda, Katarzyna
    Pacanowski, Michael A.
    Grimstein, Christian
    Zineh, Issam
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (04): : 545 - 549
  • [35] An analysis of FDA-approved drugs: natural products and their derivatives
    Patridge, Eric
    Gareiss, Peter
    Kinch, Michael S.
    Hoyer, Denton
    DRUG DISCOVERY TODAY, 2016, 21 (02) : 204 - 207
  • [36] Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs
    Lynch, Holly Fernandez
    Sachs, Rachel E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (24): : 2392 - 2393
  • [37] Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens
    Sisk, Jeanne M.
    Frieman, Matthew B.
    ACS INFECTIOUS DISEASES, 2015, 1 (09): : 401 - 402
  • [38] An analysis of FDA-approved drugs for inflammation and autoimmune diseases
    Kinch, Michael S.
    Merkel, Janie
    DRUG DISCOVERY TODAY, 2015, 20 (08) : 920 - 923
  • [39] RNA as an off-target for FDA-approved drugs
    Christopher R. Fullenkamp
    John S. Schneekloth
    Nature Chemistry, 2023, 15 : 1329 - 1331
  • [40] An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs
    Kinch, Michael S.
    Patridge, Eric
    DRUG DISCOVERY TODAY, 2014, 19 (10) : 1510 - 1513
12345